

LITERATURA

- Mulder JWCM, Kusters DM, Roeters Van Lennepe JE, Hutten BA. Lipid metabolism during pregnancy: consequences for mother and child. *Curr Opin Lipidol*. 2024;35(3):133-140. doi:10.1097/MOL.0000000000000927.
- Národní Registr Reprodukčního Zdraví. <https://www.uzis.cz/index.php?pg=registry-sber-dat--narodni-zdravotni-registry--narodni-registr-reprodukcnioh-zdravi>
- Ascarelli M, Grider A, Hsu H. Acute myocardial infarction during pregnancy managed with immediate percutaneous transluminal coronary angioplasty. *Obstet Gynecol*. 1996;88(4):655-657. doi:10.1016/0029-7844(96)00288-8.
- Karalis DG, Hill AN, Clifton S, Wild RA. The risks of statin use in pregnancy: A systematic review. *J Clin Lipidol*. 2016;10(5):1081-1090. doi:10.1016/j.jacl.2016.07.002.
- Cao L, Du Y, Zhang M, et al. High maternal blood lipid levels during early pregnancy are associated with increased risk of congenital heart disease in offspring. *Acta Obstet Gynecol Scand*. 2021;100(10):1806-1813. doi:10.1111/aogs.14225.
- Papazoglou AS, Moysidis DV, Panagopoulos P, et al. Maternal diabetes mellitus and its impact on the risk of delivering a child with congenital heart disease: a systematic review and meta-analysis. *J Matern Fetal Neonatal Med*. 2022;35(25):7685-7694. doi:10.1080/014767058.2021.1960968.
- Ryan EA, Enns L. Role of Gestational Hormones in the Induction of Insulin Resistance*. *J Clin Endocrinol Metab*. 1988;67(2):341-347. doi:10.1210/jcem-67-2-341.
- Martin-Hidalgo A, Holm C, Belfrage P, Schotz MC, Herrera E. Lipoprotein lipase and hormone-sensitive lipase activity and mRNA in rat adipose tissue during pregnancy. *Am J Physiol-Endocrinol Metab*. 1994;266(6):E930-E935. doi:10.1152/ajpendo.1994.266.6.E930.
- Wiznitzer A, Mayer A, Novack V, et al. Association of lipid levels during gestation with preeclampsia and gestational diabetes mellitus: a population-based study. *Am J Obstet Gynecol*. 2009;201(5):482.e1-482.e8. doi:10.1016/j.ajog.2009.05.032.
- Golwala S, Dolin CD, Nemiroff R, et al. Feasibility of Lipid Screening During First Trimester of Pregnancy to Identify Women at Risk of Severe Dyslipidemia. *J Am Heart Assoc*. 2023;12(10):e028626. doi:10.1161/JAHA.122.028626.
- Cuchel M, Raal FJ, Hegele RA, et al. 2023 Update on European Atherosclerosis Society Consensus Statement on Homozygous Familial Hypercholesterolaemia: new treatments and clinical guidance. *Eur Heart J*. 2023;44(25):2277-2291. doi:10.1093/eurheartj/ehad197.
- Healthy Pregnancy: What Foods to Eat When Pregnant. Last Updated 01 August 2021. <https://www.eufic.org/en/healthy-living/article/healthy-pregnancy-what-foods-to-eat-when-pregnant> (accessed on 19 July 2025).
- Davenport MH, Kathol AJ, Mottola MF, et al. Prenatal exercise is not associated with fetal mortality: a systematic review and meta-analysis. *Br J Sports Med*. 2019;53(2):108-115. doi:10.1136/bjsports-2018-099773.
- De Backer J, Haugaa KH, Hasselberg NE, et al. 2025 ESC Guidelines for the management of cardiovascular disease and pregnancy. *Eur Heart J*. 2025;46(43):4462-4568. doi:10.1093/eurheartj/ehaf193.
- Jadrnickova P, Vaclavik J, Jarkovsky J, Zouharova A. Maternal and fetal outcomes of various lipid-lowering treatment regimens during pregnancy: insights from the czech national registry 2012-2023. *Eur Heart J*. 2025;46(Supplement_1):ehaf784.3444. doi:10.1093/eurheartj/ehaf784.3444.
- FDA. Cholestyramine powder for suspension. <https://fda.report/DailyMed/ac385fd-9-fb8c-461f-959c-322c38f4515e>.
- Kondrackiene J, Beuers U, Kupcinskas L. Efficacy and Safety of Ursodeoxycholic Acid Versus Cholestyramine in Intrahepatic Cholestasis of Pregnancy. *Gastroenterology*. 2005;129(3):894-901. doi:10.1053/j.gastro.2005.06.019.
- Sadler LC, Lane M, North R. Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy. *BJOG Int J Obstet Gynaecol*. 1995;102(2):169-170. doi:10.1111/j.1471-0528.1995.tb09077.x.
- Gordon BR, Stein E, Jones P, Illingworth DR. Indications for low-density lipoprotein apheresis. *Am J Cardiol*. 1994;74(11):1109-1112. doi:10.1016/0002-9149(94)90461-8.
- Bláha V, Zadák Z, Bláha M, et al. (Selection criteria for treatment of severe hyperlipoproteinemias with LDL apheresis). *Cas Lek Cesk*. 1998;137(14):424-429.
- Makino H, Koezuka R, Tamanaha T, et al. Familial Hypercholesterolemia and Lipoprotein Apheresis. *J Atheroscler Thromb*. 2019;26(8):679-687. doi:10.5551/jat.RV17033.
- Bláha M, Veletová K, Blaha V, Lánská M, Žák P. Pregnancy in homozygous familial hypercholesterolemia—A case series. *Ther Apher Dial*. 2022;26(S1):89-96. doi:10.1111/1744-9987.13841.
- Ogura M, Makino H, Kamiya C, et al. Lipoprotein apheresis is essential for managing pregnancies in patients with homozygous familial hypercholesterolemia: Seven case series and discussion. *Atherosclerosis*. 2016;254:179-183. doi:10.1016/j.atherosclerosis.2016.10.018.
- Marlega-Linert J, Wartecka-Zielińska K, Wydra D, Fijałkowski M, Gruchala M, Mickiewicz A. Case report: lipoprotein apheresis reduces the risk of cardiovascular events and prolongs pregnancy in a woman with severely elevated lipoprotein(a), cardiovascular disease, and a high risk of preeclampsia. *Front Med*. 2023;10:1190446. doi:10.3389/fmed.2023.1190446.
- FDA Requests Removal of Strongest Warning Against Using Cholesterol-Lowering Statins During Pregnancy. Published online August 14, 2024. <https://www.fda.gov/drugs/fda-drug-safety-podcasts/fda-requests-removal-strongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy>.
- Winterfeld U, Allignol A, Panchaud A, et al. Pregnancy outcome following maternal exposure to statins: a multicentre prospective study. *BJOG Int J Obstet Gynaecol*. 2013;120(4):463-471. doi:10.1111/1471-0528.12066.
- McGrogan A, Snowball J, Charlton RA. Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss. *Pharmacoepidemiol Drug Saf*. 2017;26(7):843-852. doi:10.1002/pds.4176.
- Bateman BT, Hernandez-Diaz S, Fischer MA, et al. Statins and congenital malformations: cohort study. *BMJ*. 2015;350(mar17 10):h1035-h1035. doi:10.1136/bmj.h1035.
- Morrone D, Weintraub WS, Toth PP, et al. Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: A pooled analysis of over 21,000 subjects from 27 clinical trials. *Atherosclerosis*. 2012;223(2):251-261. doi:10.1016/j.atherosclerosis.2012.02.016.
- Wild R, Feingold KR. Effect of Pregnancy on Lipid Metabolism and Lipoprotein Levels. (Updated 2023 Mar 3). In: Feingold KR, Adler RA, Ahmed SF, et al., editors. *Endotext* (Internet). <https://www.ncbi.nlm.nih.gov/books/NBK498654/>.
- Ray KK, Kallend D, Leiter LA, et al. Effect of inclisiran on lipids in primary prevention: the ORION-11 trial. *Eur Heart J*. 2022;43(48):5047-5057. doi:10.1093/eurheartj/ehac615.
- Ardissino M, Slob EAW, Reddy RK, et al. Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations. *Eur J Prev Cardiol*. 2024;31(8):955-965. doi:10.1093/eurjpc/zwad402.
- Noseda R, Bedussi F, Panchaud A, Ceschi A. Safety of Monoclonal Antibodies Inhibiting PCSK9 in Pregnancy: Disproportionality Analysis in Vigibase®. *Clin Pharmacol Ther*. 2024;116(2):346-350. doi:10.1002/cpt.3269.
- Laffin LJ, Nicholls SJ, Scott RS, et al. Phase 1 Trial of CRISPR-Cas9 Gene Editing Targeting ANGPTL3. *N Engl J Med*. 2025;393(21):2119-2130. doi:10.1056/NEJMoa2511778.
- Middleton P, Gomersall JC, Gould JF, et al. Omega-3 fatty acid addition during pregnancy. *Cochrane Pregnancy and Childbirth Group, ed. Cochrane Database Syst Rev*. 2018;2018(11). doi:10.1002/14651858.CD003402.pub3.
- Agarwala A, Dixon DL, Gianos E, et al. Dyslipidemia management in women of reproductive potential: An Expert Clinical Consensus from the National Lipid Association. *J Clin Lipidol*. 2024;18(5):e664-e684. doi:10.1016/j.jacl.2024.05.005.
- Fruchart JC. Peroxisome proliferator-activated receptor-alpha (PPARα): At the crossroads of obesity, diabetes and cardiovascular disease. *Atherosclerosis*. 2009;205(1):1-8. doi:10.1016/j.atherosclerosis.2009.03.008.
- Grady J, Clifford C, Treadwell MC, Parikh ND, Satishchandran A. Use of fenofibrate for intrahepatic cholestasis of pregnancy. *J Hepatol*. 2023;79(2):e84-e86. doi:10.1016/j.jhep.2023.04.014.
- Arnett DK, Blumenthal RS, Albert MA, et al. 2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. *Circulation*. 2019;140(11). doi:10.1161/CIR.0000000000000678.
- Jakob T, Nordmann AJ, Schandelmaier S, Ferreira-González I, Briel M. Fibrates for primary prevention of cardiovascular disease events. *Cochrane Heart Group, ed. Cochrane Database Syst Rev*. 2016;2017(3). doi:10.1002/14651858.CD009753.pub2.
- Wanninayake S, Ochoa-Ferraro A, Patel K, Ramachandran R, Wierzbicki AS, Dawson C. Two successful pregnancies in patients taking Volanesorsen for familial chylomicronemia syndrome. *JIMD Rep*. 2024;65(4):249-254. doi:10.1002/jimd.12435.